Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden

References

• American Psychiatric Association. Diagnostic and statistical manual of mental disorders (Revised 4th ed). Washington: APA, 2000
   Google Scholar
• National Institute of Clinical Excellence. CG82 Schizophrenia: full guideline (2010). http://www.nice.org.uk/nicemedia/live/11786/43607/43607.pdf. Accessed March 8 2012
   Google Scholar
• McGrath J, Saha S, Chant D, et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 2008;30:67-76
   PubMed Web of Science ®Google Scholar
• Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull 2004;30:279-93
   PubMed Web of Science ®Google Scholar
• Lindstrom E, Eberhard J, Neovius M, et al. Costs of schizophrenia during 5 years. Acta Psychiatr Scand 2007;116:33-40
   Web of Science ®Google Scholar
• Chang SM, Cho SJ, Jeon HJ, et al. Economic burden of schizophrenia in South Korea. J Korean Med Sci 2008;23:167-75
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Baojin Zhu B, Faries DE, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry 2010;10:2
   PubMed Web of Science ®Google Scholar
• Fitzgerald P, de Castella A, Arya DS, et al. The cost of relapse in schizophrenia and schizoaffective disorder. Australas Psychiatry 2009;17:265-72
   PubMed Web of Science ®Google Scholar
• Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63:892-909
   PubMed Web of Science ®Google Scholar
• Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004;161:692-9
   PubMed Web of Science ®Google Scholar
• Sun SX, Liu GG, Christensen DB, et al. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin 2007;23:2305-12
   PubMed Web of Science ®Google Scholar
• Morken G, Widen JH, Grawe RW. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry 2008;8:32
   PubMed Web of Science ®Google Scholar
• Olivares JM, Rodriguez-Morales A, Diels J, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 2009;24:287-96
   PubMed Web of Science ®Google Scholar
• Peuskens J, Olivares JM, Pecenak J, et al. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Curr Med Res Opin 2010;26:501-9
   PubMed Web of Science ®Google Scholar
• Glazer WM, Ereshefsky L. A pharmacoeconomic model of outpatient antipsychotic therapy in ‘revolving door’ schizophrenic patients. J Clin Psychiatry 1996;57:337-45
   PubMed Web of Science ®Google Scholar
• Haycox A. Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models. Pharmacoeconomics 2005;23:3-16
   PubMed Web of Science ®Google Scholar
• Gaebel W, Schreiner A, Bergmans P, et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology 2010;35:2367-77
   PubMed Web of Science ®Google Scholar
• Kane JM, Detke HC, Naber D, et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry 2010;167:181-9
   PubMed Web of Science ®Google Scholar
• Hartung B, Wada M, Laux G, Leucht S. Perphenazine for schizophrenia. The Cochrane Collaboration, John Wiley & Sons, Ltd, Issue 5, 2010
   Google Scholar
• Kumar A, Strech D. Zuclopenthixol dihydrochloride for schizophrenia. The Cochrane Collaboration, John Wiley & Sons, Ltd, Issue 5, 2010
   Google Scholar
• Review and evaluation of clinical data. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022264s006lbl.pdf. Accessed March 8 2012
   Google Scholar
• Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 2011;14:417-28
   PubMed Web of Science ®Google Scholar
• Pandina G, Lane R, Gopal S, et al. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:218-26
   PubMed Web of Science ®Google Scholar
• Valenstein M, Copeland LA, Blow FC, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 2002;40:630-9
   PubMed Web of Science ®Google Scholar
• Ward A, Ishak K, Proskorovsky I, et al. Prescriptions for atypical antipsychotic agents and its association with the risks for hospitalisation, suicide, and death in patients with schizophrenia in Quebec and Saskatchewan: a retrospective database study. Clin Ther 2006;28:11
   Google Scholar
• Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373:31-41
   PubMed Web of Science ®Google Scholar
• Swedish national inpatient care statistics (hospitalization; average length of stay; schizophrenia diagnosis [F20]) 2008. Available at: http://192.137.163.40/epcfs/ParRes.asp. Accessed March 8 2012
   Google Scholar
• Fleischhacker WW, Gopal S, Lane R, et al. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int J Neuropsychopharmacol 2011;15:107-118
   PubMedGoogle Scholar
• Haro JM, Suarez D, Novick D, et al. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol 2007;17:235-44
   PubMed Web of Science ®Google Scholar
• Keks NA, Ingham M, Khan A, et al. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder randomised, controlled, open-label study. Br J Psychiatry 2007;191:131-9
   PubMed Web of Science ®Google Scholar
• Olanzapine pamoate Summary of Product Characteristics (Lilly) 2010
   Google Scholar
• Gopal S, Vijapurkar U, Lim P, et al. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J Psychopharmacology 2011;25:685-97
   PubMed Web of Science ®Google Scholar
• Gharabawi GM, Bossie CA, Zhu Y, et al. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study. Schizophr Res 2005;77:129-39
   PubMed Web of Science ®Google Scholar
• Schreiner A, Niehaus D, Shuriquie NA, et al. Metabolic effects with paliperidone ER versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial. J Clin Psychopharmacology 2011, in press
   Google Scholar
• Olivares JM, Rodriguez-Morales A, Diels J, et al. 24-month treatment discontinuation rates in patients with schizophrenia treated with Risperidone Long-Acting Injection (RLAI) versus oral antipsychotics: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR) in Spain. ISPOR European Annual European Congress, 20–23 October 2007; Dublin, Ireland
   Google Scholar
• Mehnert A, Diels J. Impact of administration interval on treatment retention with long-acting antipsychotics in schizophrenia. Tenth Workshop on Costs and Assessment in Psychiatry - Mental Health Policy and Economics, 25–27 March 2011; Venice, Italy
   Google Scholar
• Almond S, Knapp M, Francois C, et al. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 2004;184:346-51
   PubMed Web of Science ®Google Scholar
• Statistikdatabaser. (2008). Diagnoser i slutenvård, Socialstyrelsen, Epidemiologiskt centrum. Available at www.socialstyrelsen.se. Accessed March 8 2012
   Google Scholar
• Maehlum E, Hensen K. Pharmacoeconomic positioning of sertindole among antipsychotics in the management of schizophrenia in Norway. Value Health 2008;11:A585
   Google Scholar
• Johnson & Johnson Pharmaceuticals. Clinical study report (CSR), data on file. PSY-3001N, 2009
   Google Scholar
• Tenback De, van Harten PN, Slooff CJ, et al. Incidence and persistence of tardive dyskinesia and extrapyramidal symptoms in schizophrenia. J Psychopharmacol 2009;24:1031-5
   PubMedGoogle Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with schizophrenia. N Engl J Med 2005;353:1209-23
   PubMed Web of Science ®Google Scholar
• Ösby U, Correia N, Brandt L, et al. Mortality and causes of death in schizophrenia in Stockholm County, Sweden. Schizophr Res 2000;5:21-8
   Google Scholar
• Briggs A, Wild D, Lees M, et al. Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes 2008;6:105
   PubMed Web of Science ®Google Scholar
• LFNAR. General guidelines for economic evaluations from the Pharmaceutical Benefits Board, 2003
   Google Scholar
• Paliperidone palmitate Summary of Product Characteristics (Janssen) 2011
   Google Scholar
• World Health Organization Collaborating Centre for Drug Statistics Methodology. (2010). ATC/DDD. Available at http://www.whocc.no/atc_ddd_index/. Accessed March 8 2012
   Google Scholar
• TLV available at: http://www.tlv.se. Accessed March 8 2012
   Google Scholar
• BSC. (2009). Using the rate for Health goods for November 2009: http://www.scb.se/Pages/List____250611.aspx. Accessed March 8 2012
   Google Scholar
• Ringborg A, Martinell M, Stalhammar J, et al. Resource use and costs of type 2 diabetes in Sweden-estimates from population-based register data. Int J Clin Pract 2008;62:708-16
   PubMed Web of Science ®Google Scholar
• Drummond MD, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes. New York, USA: Oxford University Press, 2005
   Google Scholar
• Laux G, Hee BMS, van Hout BA, et al. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany. Pharmacoeconomics 2005;23:49-61
   PubMed Web of Science ®Google Scholar
• Chouinard G, Albright PS. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. J Clin Psychopharmacol 1997;17:298-307
   PubMed Web of Science ®Google Scholar
• Chue PS, Heeg BMS, Buskens E, et al. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada. Pharmacoeconomics 2005;23:62-74
   PubMed Web of Science ®Google Scholar
• Alphs L, Bossie C, Kern Sliwa J, et al. Paliperidone palmitate: clinical response in subjects with schizophrenia with recent diagnosis vs. longer-time since diagnosis. APA, 16-21 May 2009; San Francisco, USA. Poster NR6-027
   Google Scholar
• Olivares JM, Peuskens J, Pecenak J, et al. Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. Curr Med Res Opin 2009;25:2197-206
   PubMed Web of Science ®Google Scholar
• Robinson D, Woerner MG, Alvir JMJ, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999;56:241-7
   PubMed Web of Science ®Google Scholar
• Nicholl D, Akhras KS, Diels J, et al. Burden of schizophrenia in recently diagnosed patients: healthcare utilisation and cost perspective. Curr Med Res Opin 2010;26:943-55
   PubMed Web of Science ®Google Scholar